Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the organ and is now considered cured by his doctors, the Pro ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company.